

Metagenomic next-generation sequencing of cerebrospinal fluid for diagnosis of central nervous system infections: 7-year performance of a clinically validated test

Patrick Benoit^{1,2}, Noah Brazer^{1,2}, Emily Kelly¹, Venice Servellita^{1,2}, Miriam Oseguera^{1,2}, Jenny Nguyen^{1,2}, Jack Tang¹, Mikael de Lorenzi-Tognon^{1,2}, Charles Omura^{1,2}, Jessica Streithorst^{1,2}, Melissa Hillberg¹, Danielle Ingebrigtsen¹, Kelsey Zorn³, Michael Wilson^{4,5}, Tim Blicharz⁶, Amy P. Wong⁶, Brian O'Donovan⁶, Brad Murray⁶, Steve Miller^{1,6}, Charles Y. Chiu^{1,2,7,8#}

¹Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA

²UCSF-Abbott Viral Diagnostics and Discovery Center, University of California San Francisco, San Francisco, California, USA

³Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, California, USA.

⁴Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.

⁵Department of Neurology, University of California, San Francisco, San Francisco, California, USA.

⁶Delve Bio, Boston, Massachusetts, USA

⁷Department of Medicine, University of California San Francisco, California, USA

⁸Chan-Zuckerberg Biohub, San Francisco, California, USA

#Corresponding author

Charles Y. Chiu

185 Berry Street, Box #0134, San Francisco, CA 94158

(415) 420-4463

charles.chiu@ucsf.edu

Key words:

metagenomic next-generation sequencing (mNGS), central nervous system (CNS) infections, meningitis, encephalitis, meningoencephalitis, myelitis, clinical utility, infectious disease diagnosis, longitudinal analysis, microbiological testing

Abstract

Studies have shown that metagenomic next-generation sequencing (mNGS) testing of cerebrospinal fluid (CSF) in central nervous system (CNS) infections can improve diagnostic yields and provide actionable information. We analyzed the results of all CSF mNGS tests (n=4,828) performed at the University of California, San Francisco (UCSF) clinical microbiology laboratory from June 2016 to April 2023. We also assessed clinical metadata from a subset of samples that corresponded to a cohort of UCSF patients (n=1,164) who received CSF mNGS testing, and retrospectively evaluated performance compared to conventional microbiologic testing and adjudicated clinical diagnosis. Overall, 14.4% of CSF mNGS tests were positive for any microorganism. DNA viruses (7% of all samples) were detected most often, followed by RNA viruses (4.3%), bacteria (2.7%), fungi (1.4%), and parasites (0.5%). Using a composite gold standard obtained from clinical adjudication and all microbiological test results, sensitivity, specificity, and accuracy of CSF mNGS in the UCSF cohort who had clinically diagnosed infections were 56.5%, 98.8%, and 90.5%, respectively. The sensitivity of CSF mNGS testing (56.5%) was statistically higher than that from all direct detection testing from CSF (44.8%, $p = 0.004$), direct detection testing from samples other than CSF (15.2%, $p < 0.001$), and indirect serologic testing (34%, $p < 0.001$). When only considering diagnoses made by direct detection of pathogens on CSF, sensitivity of mNGS was 80.7%. These results justify the incorporation of CSF mNGS testing as part of the routine diagnostic workup in hospitalized patients presenting with potential CNS infection.

51 Introduction

52 Central nervous system (CNS) infections associated with meningitis, encephalitis, and/or myelitis can cause
53 severe and often life-threatening illness^{1,2}. Timely diagnosis and rapid initiation of appropriate therapy are
54 paramount to improve clinical outcomes in these infections, and delays have been associated with increased
55 morbidity and mortality in cases of bacterial meningitis and herpes simplex virus encephalitis^{3,4}. A complete
56 diagnostic workup for CNS infection includes a combination of culture-based, serologic, and nucleic acid
57 amplification tests (NAAT). However, despite extensive testing, it is estimated that the cause of
58 meningoencephalitis remains unknown in around 50% of cases, which hinders the initiation of appropriate and
59 targeted therapy^{5,6}.

60
61 In recent years, clinical metagenomic next-generation sequencing (mNGS) has emerged as a comprehensive
62 approach for infectious disease diagnosis, enabling simultaneous detection of a wide range of microorganisms,
63 including bacteria, viruses, fungi, and parasites, without the need to target a specific pathogen, as is required in
64 routine microbiological testing^{7,8}. This agnostic diagnostic method can be particularly useful in CNS infections
65 when the differential diagnosis is often very broad, with overlapping clinical manifestations of infectious and
66 non-infectious etiologies, and when there is limited availability of CNS samples such as cerebrospinal fluid
67 (CSF) and brain biopsy. Studies have previously shown that CSF mNGS testing in CNS infections can improve
68 diagnostic yields and provide clinically actionable information⁶.

69
70 The University of California in San Francisco (UCSF) CSF mNGS test (“UCSF mNGS test”) was developed in
71 2016; the test was analytically and clinically validated as a laboratory-developed test and is conducted in a
72 CLIA-certified laboratory⁹. The UCSF mNGS test sequences both DNA and RNA for a comprehensive
73 evaluation of infectious pathogens, and has been integrated into UCSF’s testing algorithm for cases of suspected
74 CNS infection. However, the performance of the test longitudinally and in real-life clinical settings has yet to be
75 reported. Here, we review the results from 4,828 samples tested by CSF mNGS from 2016 to 2023 to evaluate

76 (i) quality control (QC) metrics, (ii) turnaround times, and (iii) detection yields for microorganisms. We also
77 assess a subset of 1,164 samples from UCSF patients (“UCSF cohort”) by conducting a detailed chart review to
78 retrospectively evaluate test performance compared to conventional testing and adjudicated clinical diagnosis.

30 **Results**

31 **UCSF mNGS test cohort description**

32 Overall, 4,828 CSF mNGS tests were performed by the UCSF clinical microbiology laboratory from June 2016
33 to April 2023, including testing of 1,130 UCSF patients (**Table 1**). The number of tests performed increased by
34 nearly 10-fold from 116 in 2016 to 1,067 in 2022 (**Figure 1**). 55.7% of patients were male; the mean age was
35 41.5 years old with 24.2% of the cohort younger than 18 years old. Most CSF mNGS tests were performed for
36 US patients representing 46 different states (n=4,075), with 31 tests for patients from other countries (Canada
37 was the most frequent). 722 samples were sent from national or regional reference laboratories (**Figure 1**).
38 Median turnaround times for UCSF and non-UCSF patients were 8.2 and 11.4 days ($p < 0.0001$), respectively,
39 from sample collection to result, and 3.6 and 3.8 days, respectively, from start of sample processing in the
40 laboratory to result ($p < 0.0001$). The longer turnaround times from sample collection to test results for non-
41 UCSF patients may be explained by the delays between the lumbar puncture and decision to send the sample for
42 mNGS testing, delays from shipping of samples, and delays from batching of samples prior to testing.

43
44 We also evaluated QC metrics and microorganism detection yields associated with CSF mNGS testing. High
45 host background associated with presumptive reduced assay sensitivity¹⁰ was more frequently seen in DNA
46 libraries (12.2%) than in RNA libraries (1.6%). This result illustrates the interference of host DNA background
47 and the higher efficiency of DNase treatment (RNA libraries) compared to antibody-based methylated DNA
48 removal (DNA libraries) in reducing host DNA background. On the other hand, RNA libraries were more
49 difficult to amplify due to low read counts which were more frequent for RNA libraries (5.3%) than for DNA

libraries (2.6%). QC failure due to inadvertent errors in sample processing that required additional repeat testing was seen rarely (<~1%).

Out of 4,828 samples, 697 samples (14.4%) were positive for any microorganism, excluding possible or likely contaminants (**Table 1, Supplementary Dataset 1**). The annual positivity rate varied from 11.4% to 17.4%. Notably, for 2016, the positivity rate was 27%, which corresponds to the year the prospective Precision Diagnosis of Acute Infectious Diseases (PDAID) study was conducted using enrollment criteria to select patients for mNGS testing⁶. DNA viruses were most frequently identified (7% of all samples), followed by RNA viruses (4.3%), bacteria (2.7%), fungi (1.4%) and parasites (0.5%). Multiple bacterial and/or fungal taxa were detected in 7.2% of samples (348/4828) and single organisms corresponding to a commensal and/or environmental species in 3.4% of samples (164/4828). These results categories were reported more frequently for patients outside of UCSF (7.8% vs. 5.4 %, $p=0.007$ and 3.8% vs. 2%, $p=0.004$, respectively) and can be attributed to differences in CSF collection or transportation methods. These results were classified as negative since they are clinically considered likely to represent sample contamination rather than detection of etiology, as indicated in the clinical report⁶. The positivity rate in UCSF (16.2%) was higher than in non-UCSF (13.9%) patients ($p=0.05$). This difference can be explained in part by the higher rate of results for UCSF patients that were subthreshold (2.9% vs. 1.8%, $p=0.03$) (the number of reads was lower than threshold values specified in the QC metrics), and were classified as positives, based on review of patient charts, clinical presentation, and discussion with the UCSF clinical team. Overall, 2% (98/4828) positive results were reported as subthreshold. 92.3% (12/13) of *Mycobacterium tuberculosis* and 93.4 % (15/16) *Coccidioides spp.* results were reported as subthreshold. Other overrepresented organisms in this category were *Balamuthia mandrillaris*, *Histoplasma capsulatum*, West Nile virus, and Powassan virus, with 66% (2/3), 50% (2/4), 28.6% (8/28), 21.4% (3/14) of their results being reported as subthreshold, respectively (**Supplementary dataset 1**).

24 The pathogens detected with the UCSF mNGS test represented a large diversity of organisms (**Figure 2A**). A
25 total of 59 unique bacterial species were detected among the 132 positive results for bacteria (**Figure 2B**). The
26 assay detected 86 non-fastidious bacterial pathogens with 35 unique species, corresponding to bacteria that
27 traditional culture methods can detect. 46 uncommon and/or difficult-to-diagnose pathogens from 24 unique
28 species were detected such as *Mycobacterium tuberculosis*, *Nocardia farcinia*, *Leptospira borgpetersenii*,
29 *Borrelia miyamotoi*, and *Tropheryma whipplei*, corresponding to rare but definitive CNS pathogens, that are
30 fastidious or not often detected by culture (**Supplementary table 1**). The most common RNA viruses detected
31 were HIV (92), vector-borne viruses (57), and enteroviruses (16) (**Figure 2C**). Uncommon arboviruses (**Figure**
32 **2D**) such as St-Louis encephalitis virus, La Crosse virus, Cache Valley virus, and even a novel pathogen not
33 previously described in humans, Potosi virus¹¹, were detected. Various serotypes of enteroviruses could also be
34 detected, including A71 and D68, associated with acute flaccid myelitis (**Figure 2E**). Other interesting
35 pathogens detected include *Coccidioides immitis and posadasii* (16), *Cryptococcus neoformans and gattii* (13),
36 *Histoplasma capsulatum* (4), and *Fusarium spp.* (3) for fungi (**Figure 2G**), and *Toxoplasma gondii* (10),
37 *Balamuthia mandrillaris* (3), *Angiostrongylus cantonensis* (2), and *Naegleria fowleri* (1) for parasites (**Figure**
38 **2H**). Some results were also related to the initiation of outbreak investigations. For example, a vaccine strain of
39 Yellow fever virus in CSF from a transplant recipient with encephalitis was reported - this case prompted an
40 investigation by the US Centers for Disease Control of a nationwide transplant-associated outbreak¹². Also, the
41 UCSF mNGS test uncovered an outbreak of fungal meningitis with *Fusarium solani* in the US associated with
42 surgical procedures performed under epidural anesthesia in Matamoros, Mexico¹³.

43 44 **UCSF patient cohort**

45 Results from 1,164 CSF samples tested by mNGS from June 2016 to June 2023 were analyzed along with a
46 retrospective chart review of the corresponding 1052 patients (some patients had multiple CSF mNGS tests
47 performed). The UCSF cohort consisted of 223 (19.2%) cases of microbiologically confirmed CNS infection,
48 431 (37%) cases of autoimmune disease or another presumably non-infectious condition, 1 case (0.1%) of prion

19 disease, and 509 (43.7%) cases of meningitis/encephalitis with unknown etiology despite all diagnostic testing
20 including mNGS testing and longitudinal follow-up (**Table 2**). Among all UCSF patients who received the
21 UCSF mNGS test, 425 (36.5%) were immunocompromised, 1021 (87.7%) were hospitalized, 450 (38.7%) had
22 an intensive care unit (ICU) stay with a with a mean length of stay of 21.6 days, and 119 (10.2%) died within 60
23 days of admission. The average number of diagnostic tests performed was 6 from CSF and 20.2 from all
24 samples (including CSF), consisting of 28.2% (average of 5.7) culture, 24.8% (5) NAAT, 13.4% (2.7) antigen,
25 and 33.7% (6.8) serology-based assays.

26
27 For each case, we established a composite diagnosis that incorporated clinical adjudication with the results of
28 all microbiologic testing (**Supplementary dataset 2**). There were 184 (15.8%) cases of positive detection of a
29 microorganism by CSF mNGS, of which 36 (3.1%) were considered as subthreshold positive results (**Table 2**).
30 77 samples (6.6%) included incidental findings (for example, HIV detection in an HIV-infected patient with an
31 acute neurologic illness not explained by HIV) and were excluded from further analysis. 5 samples (0.4%)
32 included results of unclear significance and were also excluded (1 sample with HSV-1, 2 with CMV, 1 with
33 LCMV, and 1 with *Candida albicans*). Among results with a comment about possible contamination and
34 multiple bacterial/fungal taxa, only 2/22 (9.1%) and 1/65 (1.5%) were considered positive upon clinical review,
35 respectively, as they were clearly related to the final adjudicated diagnosis (**Supplementary table 5 and 6**).
36 Among the included mNGS positive results, 130 were true positive, where a target relevant to the adjudicated
37 diagnosis was detected, and 11 were false positive, detecting a target not relevant to the final diagnosis (**Table**
38 **3**). For the false positive results, none of the final diagnoses were due to an infectious etiology, and none of the
39 patients received treatment for the organism detected. Most of the false positive results were bacteria (75%)
40 (**Figure 4, Supplementary table 4**). 86% (31/36) of subthreshold results were considered true positive. Among
41 the mNGS negative results, 930 were true negative and 100 were false negative. Overall, CSF mNGS testing
42 exhibited a sensitivity of 56.5%, specificity of 98.8%, accuracy of 90.5%, positive predictive value (PPV) of
43 92.2% and negative predictive value (NPV) of 90.3% for CNS infections (**Table 3**). The sensitivity of CSF

mNGS (56.5%) was statistically higher than all other diagnostic modalities, including direct detection tests from CSF (44.8%, $p=0.004$), direct detection tests from samples other than CSF (16.2%, $p<0.001$), and indirect serologic detection from blood (or blood components including serum and plasma) or CSF (30.3%, $p<0.001$) (**Table 3**). A proportional Venn diagram revealed that 46 infectious diagnoses were made exclusively using the UCSF mNGS test (20% of all diagnosis), with the overlap between mNGS and other testing modalities ranging from 6 to 63 diagnoses (**Figure 3**). The UCSF mNGS test was the most sensitive diagnostic modality for RNA viruses, DNA viruses, bacteria, and parasites, but not for fungi, which was detected more often by culture and antigen detection methods. When only considering diagnosis made by direct detection of pathogen on CSF, positive percentage agreement (PPA) of mNGS was 80.7%.

As mNGS is most comparable to combined direct detection tests from CSF in the analytic principle, we analyzed discrepant results between the two diagnostic modalities. 58 infectious diagnoses were positive by CSF mNGS and not detected by another direct detection modality (**Supplementary table 2**). 33% (19/58) were not detected because no test was ordered that specifically targeted the pathogen despite the availability of such test, 17% (10/58) were not detected because a test to detect the pathogen was not readily available (e.g., Lymphocytic Choriomeningitis Virus), 14% (8/58) were not detected because the test had lower sensitivity compared to mNGS, 21% (12/58) were not detected because of fastidious microorganisms like mycobacteria and fungi that were not detectable by culture, and 15% (9/58) were not detected because antimicrobial treatment before CSF collection led to falsely negative culture (**Figure 3**). Among the 72 cases for which both the UCSF mNGS test and direct detection testing were positive, the UCSF mNGS test yielded the first reported result in 16 (22%) cases. Since most direct detection tests have a lower turnaround time, this result strongly implies that these results were first discovered by UCSF mNGS test and then confirmed by a targeted direct detection test (**Supplementary table 2**). Among 31 samples with negative mNGS results compared to positive direct detection tests, 14 (45%) were associated with high host background reducing assay sensitivity¹⁰, 6 (19%) were from patients who had received effective antimicrobial treatment prior to CSF collection, 7 (23%) was from a

low titer sample under or near the limit of detection, and 1 (3%) was due to mNGS contamination (**Figure 4**). Notably, in cases of prior effective antimicrobial treatment, all patients were antigen-positive for either *Cryptococcus sp.* or *Coccidioides sp.* following initiation of treatment for cryptococcal or coccidioidal meningitis, respectively. No clear explanation for discrepant results was found in 3 (10%) false-negative cases.

Discussion

In this study, we report the analytic results from 7 years of the UCSF mNGS test since the test's inception in 2016. We found that CSF mNGS testing was the most sensitive test for detection of pathogens in a cohort of patients with clinically severe and diagnostically challenging CNS infections, with 20% of infectious diagnoses only made by the UCSF mNGS test. The UCSF mNGS test was able to identify a broad array of pathogens that are difficult to detect using conventional methods, including novel, emerging, and/or unexpected microorganisms that are not commonly tested for. The positivity rate overall was 14.4% and was higher for UCSF than non-UCSF patients (16.2% vs. 13.9%, $p=0.05$). This difference seems to be explained by the subthreshold results for UCSF patients that were classified as positives (2.8% vs. 1.8%, $p=0.03$), where additional clinical information from chart review or communication with the primary physician in challenging cases resulted in reexamination of mNGS results that were consistent with clinical presentation. In the UCSF cohort, most positive subthreshold results (86%) were considered true positive, emphasizing the importance of carefully analyzing results to maximize the UCSF mNGS test yields and reduce the risk of false negative results, especially for high-priority pathogens such as *Mycobacterium tuberculosis* and *Coccidioides immitis*. The analysis of the clinical use of the UCSF mNGS test over 7 years demonstrate its utility and robustness, particularly in cases where routine microbiological testing fails or is less effective: (i) non-culturable, or difficult-to-culture microbes, (ii) vector-borne viruses not commonly tested for, (iii) rare or novel pathogens, (iv) outbreak investigations and (v) "rule-out" of infection.

23 (i) Non-culturable, or difficult-to-culture microbes: The UCSF mNGS test detected many organisms such as
24 fastidious bacterial species that require special incubation conditions for culture or that routinely fail to grow in
25 culture (e.g., *Bartonella henselae*, *Tropheryma whipplei*, *Borrelia burgdorferi*, and *Leptospira borgpetersenii*).
26 Additionally, the test also detected mycobacteria and fungi that can take weeks to grow in culture, including
27 *Histoplasma capsulatum*, *Aspergillus spp.*, *Rhizopus spp.*, and *Coccidioides spp.* Importantly, the UCSF mNGS
28 test enabled not only the detection of, but also subtyping of emerging fungal pathogens to the species level,
29 including *Cryptococcus gattii* and *Fusarium solani* (anamorph of *Nectria haematococca*). Lastly, fungal CNS
30 infections, such as from *Histoplasma capsulatum*, are usually difficult to diagnose, requiring a large volume of
31 CSF for culture and/or serologic detection assays performed on multiple sites for successful detection¹⁴.

32
33 (ii) Vector-borne viruses: The UCSF mNGS test detected a broad array of vector-borne viruses from the
34 *Flaviviridae* and *Peribunyaviridae* families, such as West Nile virus, Powassan virus, St-Louis virus, and Cache
35 Valley virus. Notably, serology is often considered the gold standard for these types of infections; however,
36 serological results can be challenging to interpret and have limited utility because of their low specificity, long
37 turnaround times, and limited availability in many microbiological laboratories^{15,16}. Also, for common
38 pathogens like enteroviruses, the UCSF mNGS test was able to discriminate between species and serotypes in
39 all cases of detection, unlike the typical testing method of NAAT; examples include the detection of enterovirus
40 A71 and enterovirus D68 in cases of meningoencephalitis and/or acute flaccid myelitis^{17,18}.

41
42 (iii) Rare or novel pathogens: The UCSF mNGS test was also useful in the identification of unexpected and/or
43 unusual pathogens in patients with unexplained meningoencephalitis. In many mNGS-positive cases, the
44 clinical presentation and history were atypical, the pathogen was not considered by the treating clinicians *a*
45 *priori* for testing. Examples include life-threatening amebic infections from *Balamuthia mandrillaris*,
46 *Acanthamoeba castellanii*, and *Naegleria fowleri*. The availability of diagnostic tests is limited for these
47 parasites, and detection by microscopy or NAAT on CSF is often negative, necessitating a brain biopsy to

18 establish the diagnosis¹⁹. The UCSF mNGS test could thus alleviate the need for invasive testing. Additional
19 examples of unexpected pathogens include cases of *Candida albicans*, *Toxoplasma gondii*, *Taenia solium*
20 (neurocysticercosis), *Yersinia pestis*, Lymphocytic Choriomeningitis Virus, and *Trypanosoma cruzi* - again,
21 targeted diagnostic tests for these microorganisms are available in specialty referral labs, but were not ordered
22 because there was no *a priori* suspicion.

23
24 (iv) Outbreak investigations: Results from the UCSF mNGS testing have also been used to initiate outbreak
25 investigations, especially when detecting novel pathogens that have not been described before in human
26 infections. For example, the Potosi virus, a novel *Orthobunyavirus* was detected in mosquitoes from
27 Connecticut¹¹, and a vaccine strain of yellow fever virus in CSF from a transplant recipient with encephalitis
28 was recently reported - this case prompted an investigation by the US Centers for Disease Control of a
29 nationwide transplant-associated outbreak¹². Also, the UCSF mNGS test uncovered an outbreak of fungal
30 meningitis with *Fusarium solani* in the US associated with surgical procedures performed under epidural
31 anesthesia in Matamoros, Mexico¹³.

32
33 (v) “Rule-out” of infection: In addition to detecting pathogens, the UCSF mNGS test has utility, even with
34 negative results, when infection can be confidently excluded. For example, in complex, undiagnosed cases of
35 meningoencephalitis, the differential diagnosis often includes not only infection, but also autoimmune diseases
36 such as autoantibody syndromes that are treated, often empirically, with steroids and other immunosuppressive
37 agents. Confidently ruling out infection would enable rapid deployment of immunosuppressants and ensure that
38 a yet-to-be-determined infectious etiology does not further progress. In this study, the negative predictive value
39 of CSF mNGS testing was 90.3% (vs 87% for all direct detection tests combined), which is inadequate as a
40 single test to exclude infection. However, the majority (64%) of false negative mNGS results for direct
41 detection from CSF were due either to high DNA host background (45%), a known limitation of mNGS
42 approaches^{7,10}, or persistent antigen positivity from fungal infection after onset of treatment (19%). Regarding

73 the latter, it is known that antigens can persist after sterilization in cases of cryptococcal meningitis and that
74 persistent antigen positivity does not correlate with worse clinical outcomes²⁰. Thus, in most CSF samples,
75 which do not have high background, a combination of mNGS and other tests such as fungal antigen testing may
76 be sufficient for direct detection of pathogens causing CNS infections in CSF.

77
78 This study is different than the prospective PDAID study carried out in 2016 to evaluate the performance and
79 clinical impact of the UCSF mNGS test⁶. In the current study, the UCSF mNGS test is performed as a reference
80 laboratory test with samples sent out from multiple health institutions, and results are reported with minimal
81 clinical information on patients. The inclusion criteria for performing the UCSF mNGS tests are also less
82 stringent (see methods) than in a prospective study with carefully selected populations. Since the publication of
83 the PDAID study, the likelihood of reporting positive subthreshold results has increased, after noting in the
84 study that thresholds were too conservative for some high-priority pathogens present in low abundance in
85 samples. Even with these differences, the sensitivity of the assay is similar between the two studies. When only
86 considering diagnosis made by direct detection of pathogen DNA/RNA on CSF, PPA of mNGS was 80.7% in
87 this study and 80.0% in the PDAID study.

88
89 Finally, our study also highlights the limits of the UCSF mNGS test. While the test showed clear utility when
90 compared to direct detection methods on CSF, there are clinical situations where the causative pathogen is
91 absent in CSF and can be found only in brain tissue or well-encapsulated brain abscesses²¹. Additionally, in
92 cases of “hit-and-run” exposure, the window of direct detection in CSF may be brief, such as for West Nile
93 virus meningoencephalitis²². In these cases, diagnostic methods based on detecting pathogens outside of the
94 CNS and/or indirect detection, such as serology, are still useful, and host transcriptome analysis through mNGS
95 appears promising to enhance diagnosis^{23,24}.

There are several limitations to our study. Although we report the largest cohort to date evaluating the clinical and diagnostic utility of CSF mNGS in, diagnostically- and clinically-challenging cases of CNS infections, the extent of the diagnostic workup, including types of diagnostics used and clinical decision-making varied widely from case to case, making it difficult to evaluate the side-by-side performance of mNGS compared to other tests, in real-time. Bias may have also been introduced by the use of a composite diagnosis generated from all microbiological test results and clinical adjudication, since a single or consensus gold standard for mNGS has not been established. However, this bias was minimized by conducting three independent assessments. Finally, this study did not evaluate some outstanding questions related to the UCSF mNGS test, including (i) the impact on the clinical management and treatment of patients with CNS infections, (ii) patient characteristics that would maximize diagnostic yield such as transplant, immunocompromised, or pediatric populations, and (iii) the timing and cost-effectiveness of incorporating mNGS into testing algorithms. In today's clinical workflow, mNGS is often described as the "test of last resort"; however, using mNGS earlier in patient's clinical course may lead to earlier diagnoses that enable deployment of appropriate and tailored therapy. Ultimately, this might lower healthcare costs, particularly in the in-patient setting where average costs of stays for meningitis/encephalitis cases are over \$15,000²⁵. The results presented illustrate the clinical utility and yield of including mNGS to the arsenal of diagnostic tools used to investigate and complete the diagnostic workup of patients with suspected CNS infections.

Methods

CSF mNGS testing

The UCSF mNGS test was developed to facilitate the broad identification of pathogens in diagnostically challenging CNS infections. The previously reported assay workflow⁹ consisted of (i) nucleic acid extraction, (ii) microbial enrichment using antibody-based removal of methylated host DNA for DNA libraries and DNase treatment for RNA libraries, (iii) library preparation and pooling in equimolar concentrations, and (iv) sequencing on an Illumina (San Diego, California) instrument targeting 5 – 20 million sequences per library.

22 Raw sequences were analyzed using SURPI+, a bioinformatic analysis pipeline for pathogen identification that
23 was modified for clinical use²⁶. Automatically generated results from SURPI+ included heat maps of raw and
24 normalized read counts per million (RPM) for each sample and an mNGS results summary in an Excel
25 spreadsheet. A laboratory director (CC or SM) interpreted and reviewed the results before reporting the
26 findings.

27
28 Quality control (QC) metrics for the assay included a minimum of 5 million preprocessed reads per sample,
29 >75% of data with quality score >30 (Q>30), and successful detection of all seven representative organisms in
30 the positive control and the internal spiked T1 and MS2 phage controls. A threshold criterion of ≥ 3 non-
31 overlapping viral reads aligning to the target viral genome was considered a positive detection for virus
32 identification. An RPM ratio threshold of 10 was considered positive for bacteria, fungi, and parasite detection⁹.
33 Following the completion of a prospective study to evaluate clinical utility and diagnostic yield⁶, the reporting
34 algorithm was modified to include additional comments regarding subthreshold detections of likely clinically
35 relevant organisms (for example, *Mycobacterium tuberculosis* and *Coccidioides immitis*) at the discretion of the
36 laboratory director. If the T1 (DNA library) and/or MS2 (RNA library) spiked internal control RPM is <100,
37 indicating high host background, or the number of preprocessed reads is below the established cutoff of 5
38 million, negative CSF mNGS results are reported with an added comment regarding the potential for decreased
39 sensitivity for organisms with a genome of that library type.

40 41 **Patient Cohorts**

42 The UCSF mNGS test results analyzed in this study (n=4,828) included those from samples received from June
43 2016 to April 2023; samples came from both within and outside the UCSF Health network. Patient
44 demographic information that was available included age, sex, and geographic location by state. Clinical
45 information was available for a subset of cases – those for which the detection of an unusual microorganism
46 prompted a clinical microbial sequencing board (CMSB) discussion with the treating provider and those which

were from UCSF patients (“UCSF cohort”). QC metrics and sequencing results were evaluated, along with overall turnaround time (sample collection to result) and laboratory turnaround time (start of processing to result).

The UCSF cohort (n=1,164) from June 2016 to June 2023 was assessed by retrospective chart review to determine the performance and utility in diagnosing CNS infections compared to other assays. All requests for the UCSF mNGS test were reviewed by the laboratory director, and testing was approved if patients met one of more of the following criteria: (i) CSF pleocytosis, (ii) brain biopsy that suggested a likely infectious etiology, (iii) immunocompromised patient with strong suspicion for infection based on clinical presentation, laboratory testing, and/or radiographic imaging, and (iv) recommendation for mNGS testing after neurology and/or infectious diseases consultation. A final composite diagnosis for the UCSF cohort was established through clinical adjudication and review of all diagnostic tests (mNGS and other conventional microbiological testing); this composite diagnosis was performed independently by three infectious disease physicians (PB, MLT and CYC) and categorized results as bacterial, viral, fungal, parasitic, non-infectious/autoimmune, prion-associated, or unknown. Any discrepancies in the final diagnosis were resolved by mutual agreement after re-review and discussion. A case was considered infectious when at least one test result (mNGS or conventional) was positive. All tests relevant to the final diagnosis were recorded for each patient and assigned to 1 of 4 different categories: (1) mNGS; (2) direct detection testing on CSF (culture, antigen detection, and NAAT); (3) direct detection testing sample types other than CSF, such as brain biopsy tissue and/or plasma (culture, antigen detection, and NAAT); and (4) indirect serologic testing from CSF or blood. For each positive test, the turnaround time from sample collection to test result was also recorded. mNGS results were further classified as (i) positive, (ii) single organism with possible contamination, (iii) multiple bacterial/fungal taxa (probable contamination), (iv) incidental findings (organisms detected that are not linked to the CNS infection pathogenesis were not considered a false positive, e.g. detection of HIV detection in an HIV-infected individual), or (v) unclear significance (organisms that were detected and were possibly associated with the

infection without any possible confirmation). For the performance analysis, possible and probable contaminants were considered as negative, unless clearly related to the final adjudicated diagnosis. Incidental and unclear significance results were excluded from analysis. A complete review of the adjudication process is available as a **supplementary file**.

Statistical analysis

Statistical analyses were performed using R Statistical Software (version 4.3.1). Mann-Withney test was used to assess differences in turnaround time. Chi-square testing was used to compare sequencing results yields incorporating individual organism categories. The McNemar test was used to compare sensitivity and specificity differences between diagnostic methods and mNGS testing. Proportional Venn diagrams were constructed using DeepVenn²⁷.

Ethics approval

Retrospective patient chart review and analysis of patient clinical CSF results were performed under a biobanking protocol with waiver of consent approved by the UCSF Institutional Review Board.

Resource availability

Lead Contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Charles Chiu (charles.chiu@ucsf.edu).

Materials Availability

This study did not generate any new reagents.

Data and Code Availability

07 The data that support the findings of this study are available on request from the corresponding author C.Y.C.
08 The sequencing data are not publicly available because they contain information that could compromise
09 research participants' privacy/consent.

10

11 **Acknowledgement**

12 We thank the staff at the UCSF Clinical Microbiology Laboratory for performing the UCSF mNGS test. This
13 work was funded, in part, by Delve Bio.

14

15 **Competing interests**

16 A.P.W., B.O., and S.M. are employed by and own equity in Delve Bio. C.Y.C. is a founder of Delve Bio and on
17 the scientific advisory board for Delve Bio, Flightpath Biosciences, Biomeme, Mammoth Biosciences,
18 BiomeSense and Poppy Health. He is also an inventor on US patent 11380421, “Pathogen detection using next
19 generation sequencing”, under which algorithms for taxonomic classification, filtering and pathogen detection
20 are used by SURPI+ software. C.Y.C. receives research support from Delve Bio and Abbott Laboratories, Inc.

21

22 **Authors contribution**

23 P.B., N.B., E.K., V.S., A.P.W., B.O., B.M., S.M and C.Y.C conceived and designed the study. P.B., N.B.,
24 M.O., J.N., J.T., M.H., M.L.T., D.I. collected the data. P.B., E.K., V.S., M.L.T., A.P.W., B.O., S.M., and C.Y.C.
25 analyzed data. P.B., E.K., and C.Y.C. wrote the manuscript. P.B., E.K., and C.Y.C. prepared the figures. P.B.,
26 N.B., E.K., V.S., M.O., J.N., J.T., M.L.T., C.O., K.Z., M.W., T.B., M.H., D.I., A.P.W., B.O., B.M., S.M., and
27 C.Y.C. edited the manuscript. All authors read the manuscript and agree to its contents.

28

29

30

21 **Tables**

22 Table 1. UCSF mNGS test characteristics for 4828 samples performed from 2016 to 2023.

Demographics			
Sex (n = 4596)			
Male	2558 (55.7%)		
Age (n = 4810)			
<18	1164 (24.2%)		
18-65	2638 (54.8%)		
>65	1003 (20.9%)		
Years	Number of tests done	Positivity rate	
2016	116 (2.4%)	31 (26.7%)	
2017	256 (5.3%)	44 (17.2%)	
2018	439 (9.1%)	50 (11.4%)	
2019	726 (15%)	99 (13.6%)	
2020	822 (17%)	136 (16.5%)	
2021	1032 (21.3%)	132 (12.8%)	
2022	1067 (22.1%)	141 (13.2%)	
2023 ^a	370 (7.6%)	61 (16.5%)	
Quality control metrics			
High human background DNA library	589 (12.2%)		
High human background RNA library	79 (1.6%)		
Low reads DNA library ^b	124 (2.6%)		
Low reads RNA library	255 (5.3%)		
DNA library QC failure ^c	52 (1.1%)		
RNA library QC failure	38 (0.8%)		
Median turnaround time			
	Total (n = 4828)	UCSF (n=1130)	Non-UCSF (n=3698)
Analytic turnaround time [IQR]	3.7 [3.3,5.0]	3.6 [3.3,4.6]	3.8 [3.3,5.2]
Total turnaround time [IQR]	10.5 [8.4,14.2]	8.2 [6.3,10.1]	11.4 [9.2,15.1]
			P < 0.0001 ^d
			P < 0.0001
Sequencing results^e			
	Total (n = 4828)	UCSF (n=1130)	Non-UCSF (n=3698)
Positive samples, excluding possible or likely contaminant ^f	697 (14.4%)	183 (16.2%)	514 (13.9%)
Bacteria	132 (2.7%)	33 (2.9%)	99 (2.7%)
DNA virus	341 (7%)	98 (8.6%)	243 (6.6%)
RNA virus	206 (4.3%)	50 (4.4%)	156 (4.2%)
Fungi	68 (1.4%)	25 (2.2%)	43 (1.2%)
Parasite	23 (0.5%)	11 (1%)	12 (0.3%)
Subthreshold results ^g	98 (2%)	32 (2.8%)	66 (1.8%)
Single organism, possible contamination ^h	164 (3.4%)	23 (2%)	141 (3.8%)
Multiple bacterial/fungal taxa probable contaminant ⁱ	348 (7.2%)	61 (5.4%)	287 (7.8%)
			P = 0.05
			P = 0.03
			P = 0.004
			P = 0.007

23 ^aData are up to April 2023. ^bLow reads comment is added when <5 million preprocessed reads are sequenced for a library. Results are
24 reported, but interpretation might be affected. ^cLibrary QC failure represents any analytic problem that led to invalid results.
25 ^dComparison of turnaround time was done with the Mann-Whitney test ^e Percentages for each category are based on the total number
26 of samples since one sample can be positive for more than one target. ^f Samples with multiple taxa detected for bacteria/fungi were
27 considered negative since they represent likely contamination. Samples with single detected taxa corresponding to a commensal
28 and/or environmental microorganism and reported with a comment about potential contamination were also considered negative.

29 ^gSubthreshold results correspond to positive results below the specified QC metrics that are considered likely clinically relevant
30 organisms (for example, *Mycobacterium tuberculosis* and *Coccidioides immitis*) and reported at the discretion of the laboratory
31 director. ^hSamples with single detected taxa corresponding to a commensal and/or environmental microorganism and reported with a
32 comment about potential contamination (considered negative in this table). ⁱSamples with multiple taxa detected for bacteria and fungi
33 were considered as negative since they represent likely contamination.

34 Table 2. Subset analysis from the UCSF cohort (n = 1164).

Demographics		
Male Sex		643 (55.2%)
Age		
<18		169 (14.5%)
18-65		711 (61.1%)
>65		284 (24.4%)
Immunosuppression		
Any immunosuppression		425 (36.5%)
Human immunodeficiency virus (HIV)		52 (4.5%)
Solid organ transplant		63 (5.4%)
Hematopoietic stem cell transplant		49 (4.2%)
Chemotherapy		47 (4%)
Immunomodulators		101 (8.7%)
Primary immunodeficiency		18 (1.5%)
Other		95 (8.2%)
Primary clinical syndrome		
Meningitis		293 (25.2%)
Encephalitis		293 (25.2%)
Meningoencephalitis		202 (17.4%)
Myelitis		69 (5.9%)
None or Unknown		307 (26.3%)
Clinical Setting and outcome		
Inpatient		1021 (87.7%)
ICU		450 (38.7%)
Length of stay (Mean)		21.6
Death at 60 days		119 (10.2%)
mNGS results		
Any positive result ^a		184 (16.7%)
Single organism, possible contamination ^b		23 (2%)
Multiple bacterial/fungal taxa probable contaminant ^c		65 (5.6%)
Incidental findings ^d		77 (6.6%)
Subthreshold results ^e		36 (3.1%)
Unclear significance ^f		5 (0.4%)
Final diagnosis etiology^g		
Auto-immune/Non-infectious		431 (37%)
Prion		1 (0.09%)
Unknown		509 (43.7%)
Infectious		223 (19.2%)
Infectious diagnosis category	Total number of diagnosis (n=230 ^h)	Number positive by mNGS
Bacterial	57 (24.8%)	26 (45.6%)
DNA virus	70 (30.4%)	50 (71.4%)
RNA virus	32 (13.9%)	20 (62.5%)
Fungal	50 (21.7%)	22 (44%)
Parasitic	21 (9.1%)	12 (57.1%)

35 ^aSamples with multiple taxa detected for bacteria/fungi were considered negative since they represent likely contamination. Samples
36 with single detected taxa corresponding to a commensal and/or environmental microorganism and reported with a comment about
37 potential contamination were also considered negative unless clearly related to the final adjudicated diagnosis. ^bSamples with single
38 detected taxa corresponding to a commensal and/or environmental microorganism and reported with a comment about potential
39 contamination were considered negative unless clearly related to the final adjudicated diagnosis. ^cSamples with multiple taxa detected
40 for bacteria/fungi were considered negative since they represent likely contamination unless clearly related to the final adjudicated
41 diagnosis. ^dIncidental findings are organisms detected that are not linked to the CNS infection pathogenesis but that are also not a
42 false positive detection (for example, HIV detection in an HIV-infected individual). ^eSubthreshold results correspond to positive
43 results below the specified QC metrics that are considered likely clinically relevant organisms (for example, *Mycobacterium*
44 *tuberculosis* and *Coccidioides immitis*) and reported at the discretion of the laboratory director. ^fOrganisms that were detected and
45 were possibly contributive to the infection without any possible confirmation (e.g. Findings were not confirmed because the patient
46 died or other organisms were thought to explain better the patient's symptoms). ^gClinical adjudication was performed to determine the
47 etiology of the clinical syndrome by chart-review. To be considered an infectious process, at least one microbiological test had to be
48 positive, and consistent with the clinical adjudication. ^hSix cases were caused by one than more organism and were included in each
49 respective category.
50

51 Table 3. Clinical performance of diagnostic methods for diagnosis of CNS infections.

		Gold standard ^a		Clinical Sensitivity (%)	Clinical Specificity (%)	Clinical Accuracy (%)	PPV (%)	NPV (%)
		Positive	Negative					
mNGS	Positive	130	11 ^b	56.5	98.8	90.5	92.2	90.3
	Negative	100	930					
Direct detection on CSF ^c	Positive	103	51	44.8 (p=0.004) ^f	94.3 (p<0.001)	84.3	66.9	87.0
	Negative	127	851					
	Not done	41						
Direct detection on other specimens than CSF ^d	Positive	37	16	16.2 (p<0.001)	98.3 (p=0.3)	81.9	69.8	82.5
	Negative	192	906					
	Not done	20						
Indirect serologic detection ^e	Positive	61	0	30.3 (p<0.001)	100.0 (p<0.001)	85.8	100.0	84.9
	Negative	140	787					
	Not done	183						

52
53 ^aGold standard is a clinical adjudication process. Every sample was evaluated to determine the causative organism(s). If there was
54 more than one causative organism, each organism was considered individually. TP, FP, FN, TN was assigned for each diagnostic
55 method in regard to the individual causative organism. If two categories applied (a FP result on mNGS also missed the true diagnosis
56 (FN)), we assigned 1 to each category. We assigned "not done" if no test of this category was done for a specific sample and excluded
57 this sample from performance calculations. The breakdown of the adjudication process is available in **Supplementary dataset 2**.

58 ^bResults with multiple bacterial/fungal taxa or comments regarding possible contamination were considered as negative unless clearly
59 related to the final diagnosis. Organisms detected that are not linked to the CNS infection pathogenesis but that are also not a false
60 positive detection were classified as incidental findings (e.g. HIV, HHV6, HHV7) and not considered for performance calculations.
61 Organisms that were detected and were possibly contributive to the infection without any possible confirmation (e.g. Findings were
62 not confirmed because the patient died or other organisms were thought to explain better the patient's symptoms) were classified as
63 unclear significance findings and were not included for performance calculations. ^cIncludes all direct detection tests done on CSF
64 such as culture, antigen detection, specific and universal NAATs. ^dIncludes all direct detection tests done on tissue, blood, and
65 respiratory samples such as culture, antigen detection, specific and universal NAAT. ^eIncludes all antibody detection (serologic) test
66 done on CSF or blood. ^fp-value is based on comparison with mNGS by McNemar test. TP: True positive, FP: False positive, FN:
67 False negative, TN: True negative, NAAT : Nucleic acid amplification test, CSF: Cerebrospinal fluid.
68
69

70 **Figures**

71 **Figure 1. Distribution of tests ordered by year and by location.** Distribution of tests ordered by State,
72 internationally, and from reference laboratories. A total of 4075 tests were from the United States, California
73 being the most frequent State of origin (n = 2420 samples). Reference laboratories such as ARUP, Labcorp, and
74 Mayo Clinic Laboratories (n=722) receive tests from multiple States, so individual samples couldn't be retraced
75 and, therefore, excluded from the figure. 14.8 % (n = 715) of samples were sent from hospitals dedicated to the
76 care of pediatric patients. * Data are up to April 2023.

77
78 **Figure 2. Summary of positive results by mNGS (n=4828).** (A) Summary of positive UCSF mNGS test
79 results by microorganism type. One test can be positive for more than one target. (B) A total of 59 unique
80 species with a total of 132 cases were detected by the assay. 88 pathogens that can be detected by traditional
81 culture methods corresponding to 35 unique species were detected. 46 uncommon and/or difficult-to-diagnose
82 bacteria, corresponding to rare but definitive CNS pathogens, that are fastidious or not detected by culture. The
83 list of bacterial pathogens detected is available in **supplementary table 1**. (C) The most common RNA viruses
84 detected were HIV (92), vector-borne viruses (57), and enteroviruses (16). Other RNA viruses detected include
85 Lymphocytic Choriomeningitis virus (3), Astrovirus (2), Calicivirus (2), Coronavirus 229E (2), SARS-CoV-2
86 (1), HTLV-2 (1), Human parechovirus (1), Measles virus (1). (D) Vector-borne viruses, a diverse and clinically
87 important group, are typically challenging to diagnose by traditional methods because they require specific
88 NAAT or serologies for each virus, whereas mNGS can detect a broad range of pathogens in a single assay.
89 *Orthobunyaviruses* detected included Cache Valley virus (3), Jamestown Canyon virus (1) La Crosse virus (1),
90 Potosi virus (1). Of interest, the Potosi virus is a novel species in this genus, not reported before as causing
91 diseases in humans¹¹. (E) One of the strengths of the assay is its ability to discriminate between species and
92 serotypes, unlike the typical testing method of NAAT. For instance, the assay detected various subtypes of
93 enteroviruses and five cases of A71 and D68 associated with acute flaccid myelitis. (F) Other DNA viruses
94 detected included Human parvovirus 4 and B-19 (4) and HHV-8 (1). (G) Other fungi detected included

15 *Alternaria spp.* (2), *Mucorales spp.* (2), *Epicoccum spp.* (1), and *Sporothrix schenckii* (1). (H) The assay
16 detected challenging parasitic infections to diagnose, such as *Toxoplasma gondii* (10), *Balamuthia mandrillaris*
17 (3), *Angiostrongylus cantonensis* (2), and *Naegleria fowleri* (1). HCV: Hepatitis C virus, HEV: Hepatitis E
18 virus, HIV: Human immunodeficiency virus, EV: Enterovirus, EBV: Epstein-Barr virus, CMV:
19 Cytomegalovirus, HHV-6: Human herpes virus 6, HHV-7: Human herpes virus 7, VZV: Varicella-zoster virus,
20 HSV: Herpes simplex virus, NAAT: Nucleic acid amplification test.

21
22 **Figure 3. Comparison of each diagnostic modality in obtaining a final diagnosis and analysis of positive**

23 **mNGS results. (A)** The proportional Venn diagram represents the overlap between diagnostic modalities, with
24 CSF mNGS and direct detection on CSF having the biggest overlap due to the similarity in the analytic
25 principle (detection of pathogen). A substantial number of diagnoses were made only by indirect serologic
26 methods (44), and direct detection on samples other than CSF (24). The total number of diagnoses is 230 (Six
27 cases were attributed to more than one causative organism and were considered individually for this analysis).
28 Diagnoses made by mNGS that were negative by direct detection methods (n=58) included common
29 (Cytomegalovirus (CMV), Coxsackieviruses, *Streptococcus pneumoniae*) and rare pathogens (Lymphocytic
30 Choriomeningitis virus, *Ureaplasma parvum*, *Balamuthia mandrillaris*). When the diagnosis was made by both
31 mNGS and direct detection methods on CSF, 16/72 (22%) were made faster by mNGS, implying that most of
32 these diagnoses were, in fact, made by mNGS and confirmed by a secondary analysis. These results are
33 available in **supplementary table 2. (B)** CSF mNGS detected the most cases of RNA viruses, DNA viruses,
34 bacteria, and parasites, but not for fungi, which was detected more often by culture and antigen detection
35 methods. (C) The most common discrepant factor to explain an mNGS positive result and a negative direct
36 detection method on CSF was failure to specifically test for the pathogen when a test was readily available
37 (33%), inability to culture a fastidious micro-organism (21%), failure to specifically test for the pathogen when
38 there is no readily available test (17%), prior antimicrobial therapy with negative culture at time of CSF
39 collection (15%), and inferior sensitivity of conventional tests compared to mNGS (14%).

20 **Figure 4. Analysis of false negative and false positive mNGS results.** (A) 31 samples were positive by direct
21 detection methods on CSF and negative by mNGS. 64% of the false negative results were attributed to either
22 high DNA host background (45%), a known limitation of mNGS approaches^{7,10}, or persistent antigen positivity
23 from fungal infection after onset of treatment (19%). The list of mNGS false negative results is available in
24 **supplementary table 3.** (B) False positive results were infrequent (n=11), with a majority of bacteria detected
25 (75%). None of these mNGS results were acted upon, and all pathogens detected by mNGS were not
26 compatible with the clinical presentation of the patient. The list of false positive results is available in
27 **supplementary table 4.**


28 References

- 29
- 30 1 Bloch, K. C., Glaser, C., Gaston, D. & Venkatesan, A. State of the Art: Acute Encephalitis. *Clin Infect*
31 *Dis* **77**, e14-e33 (2023). <https://doi.org/10.1093/cid/ciad306>
- 32 2 Swartz, M. N. Bacterial meningitis--a view of the past 90 years. *N Engl J Med* **351**, 1826-1828 (2004).
33 <https://doi.org/10.1056/NEJMp048246>
- 34 3 Koster-Rasmussen, R., Korshin, A. & Meyer, C. N. Antibiotic treatment delay and outcome in acute
35 bacterial meningitis. *J Infect* **57**, 449-454 (2008). <https://doi.org/10.1016/j.jinf.2008.09.033>
- 36 4 Poissy, J. *et al.* Factors associated with delay to acyclovir administration in 184 patients with herpes
37 simplex virus encephalitis. *Clin Microbiol Infect* **15**, 560-564 (2009). [https://doi.org/10.1111/j.1469-
38 0691.2009.02735.x](https://doi.org/10.1111/j.1469-0691.2009.02735.x)
- 39 5 Glaser, C. A. *et al.* Beyond viruses: clinical profiles and etiologies associated with encephalitis. *Clin*
40 *Infect Dis* **43**, 1565-1577 (2006). <https://doi.org/10.1086/509330>
- 41 6 Wilson, M. R. *et al.* Clinical Metagenomic Sequencing for Diagnosis of Meningitis and Encephalitis. *N*
42 *Engl J Med* **380**, 2327-2340 (2019). <https://doi.org/10.1056/NEJMoa1803396>
- 43 7 Chiu, C. Y. & Miller, S. A. Clinical metagenomics. *Nat Rev Genet* **20**, 341-355 (2019).
44 <https://doi.org/10.1038/s41576-019-0113-7>
- 45 8 Miller, S. & Chiu, C. The Role of Metagenomics and Next-Generation Sequencing in Infectious Disease
46 Diagnosis. *Clin Chem* **68**, 115-124 (2021). <https://doi.org/10.1093/clinchem/hvab173>
- 47 9 Miller, S. *et al.* Laboratory validation of a clinical metagenomic sequencing assay for pathogen
48 detection in cerebrospinal fluid. *Genome Res* **29**, 831-842 (2019). <https://doi.org/10.1101/gr.238170.118>
- 49 10 Schlaberg, R. *et al.* Validation of Metagenomic Next-Generation Sequencing Tests for Universal
50 Pathogen Detection. *Arch Pathol Lab Med* **141**, 776-786 (2017). [https://doi.org/10.5858/arpa.2016-
51 0539-RA](https://doi.org/10.5858/arpa.2016-0539-RA)


- 52 11 Armstrong, P. M., Andreadis, T. G., Anderson, J. F. & Main, A. J. Isolations of Potosi virus from
53 mosquitoes (Diptera: Culicidae) collected in Connecticut. *J Med Entomol* **42**, 875-881 (2005).
54 <https://doi.org/10.1093/jmedent/42.5.875>
- 55 12 Gould, C. V. *et al.* Transmission of yellow fever vaccine virus through blood transfusion and organ
56 transplantation in the USA in 2021: report of an investigation. *Lancet Microbe* **4**, e711-e721 (2023).
57 [https://doi.org/10.1016/S2666-5247\(23\)00170-2](https://doi.org/10.1016/S2666-5247(23)00170-2)
- 58 13 CDC. Fungal Meningitis Outbreak Associated with Procedures Performed under Epidural Anesthesia in
59 Matamoros, Mexico. (2023).
- 50 14 Wheat, J. *et al.* Central nervous system histoplasmosis: Multicenter retrospective study on clinical
51 features, diagnostic approach and outcome of treatment. *Medicine (Baltimore)* **97**, e0245 (2018).
52 <https://doi.org/10.1097/MD.00000000000010245>
- 53 15 Madison-Antenucci, S., Kramer, L. D., Gebhardt, L. L. & Kauffman, E. Emerging Tick-Borne Diseases.
54 *Clin Microbiol Rev* **33** (2020). <https://doi.org/10.1128/CMR.00083-18>
- 55 16 Martin, D. A. *et al.* Use of immunoglobulin m cross-reactions in differential diagnosis of human
56 flaviviral encephalitis infections in the United States. *Clin Diagn Lab Immunol* **9**, 544-549 (2002).
57 <https://doi.org/10.1128/cdli.9.3.544-549.2002>
- 58 17 Holm-Hansen, C. C., Midgley, S. E. & Fischer, T. K. Global emergence of enterovirus D68: a
59 systematic review. *Lancet Infect Dis* **16**, e64-e75 (2016). [https://doi.org/10.1016/S1473-3099\(15\)00543-](https://doi.org/10.1016/S1473-3099(15)00543-5)
60 [5](https://doi.org/10.1016/S1473-3099(15)00543-5)
- 61 18 Perez-Velez, C. M. *et al.* Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge.
62 *Clin Infect Dis* **45**, 950-957 (2007). <https://doi.org/10.1086/521895>
- 63 19 Cope, J. R. *et al.* The Epidemiology and Clinical Features of Balamuthia mandrillaris Disease in the
64 United States, 1974-2016. *Clin Infect Dis* **68**, 1815-1822 (2019). <https://doi.org/10.1093/cid/ciy813>

- 75 20 Singh, N., Dromer, F., Perfect, J. R. & Lortholary, O. Cryptococcosis in solid organ transplant
76 recipients: current state of the science. *Clin Infect Dis* **47**, 1321-1327 (2008).
77 <https://doi.org/10.1086/592690>
- 78 21 Heilpern, K. L. & Lorber, B. Focal intracranial infections. *Infect Dis Clin North Am* **10**, 879-898 (1996).
79 [https://doi.org/10.1016/s0891-5520\(05\)70331-7](https://doi.org/10.1016/s0891-5520(05)70331-7)
- 30 22 Busch, M. P. *et al.* Virus and antibody dynamics in acute west nile virus infection. *J Infect Dis* **198**, 984-
31 993 (2008). <https://doi.org/10.1086/591467>
- 32 23 Ramachandran, P. S. & Wilson, M. R. Metagenomics for neurological infections - expanding our
33 imagination. *Nat Rev Neurol* **16**, 547-556 (2020). <https://doi.org/10.1038/s41582-020-0374-y>
- 34 24 Ramachandran, P. S. *et al.* Integrating central nervous system metagenomics and host response for
35 diagnosis of tuberculosis meningitis and its mimics. *Nature Communications* **13**, 1675 (2022).
36 <https://doi.org/10.1038/s41467-022-29353-x>
- 37 25 Balada-Llasat, J. M. *et al.* Cost of managing meningitis and encephalitis among adult patients in the
38 United States of America. *Int J Infect Dis* **71**, 117-121 (2018). <https://doi.org/10.1016/j.ijid.2018.04.799>
- 39 26 Naccache, S. N. *et al.* A cloud-compatible bioinformatics pipeline for ultrarapid pathogen identification
40 from next-generation sequencing of clinical samples. *Genome Res* **24**, 1180-1192 (2014).
41 <https://doi.org/10.1101/gr.171934.113>
- 42 27 Hulsen, T. DeepVenn -- a web application for the creation of area-proportional Venn diagrams using the
43 deep learning framework Tensorflow.js. *arXiv* (2022).
44 <https://doi.org/https://doi.org/10.48550/arXiv.2210.04597>
- 45
46

Number of tests by year












United States




International

Brazil (1), Colombia (1),
Latvia (1), Portugal (1)







Diagnosis by test method




Positive results by test method and type of organism




Discrepancy between positive mNGS and negative direct detection on CSF (n=58)



A**False negative results (n=31)**

- High human background
- Low positive sample
- Unknown
- Treated before CSF collection
- mNGS contamination

B**False positive results by organism (n=12)**

- DNA virus
- RNA virus
- Bacteria
- Fungi